Wissen Sie, ob Romark klinische Studien zur Tripletherapie mit Alinia auch in Europa plant? Ich w
Do you have any thoughts on vx-950?? Thanks
I was curious about a couple of comments you made in passing:
(1) regarding nitazoxanide's possible mode of anti-viral action as promoting misfolding of a viral potein . Which protein? Is additional information available regarding this ?
(2) "increase cancer risk anywhere near ribavirin". I've always been bothered by the fact that ribavirin, a presumed viral mutagen and a known teratogen, specifies in its drug spec sheet that mutagenic studies have never been completed. Does your comment indicate there might be good reason for this omission?
re nitazoxanide, I didn't find much in the <a href="http://www.fda.gov/medwatch/SAFETY/2005/Jun_PI/Alinia_PI.pdf">FDA drug sheet</a> to worry about. Though only approved in '04 I got the impression it had been used in a veterinary context for much longer.
No further details about Nitazoxanide's "protein folding interaction" are available anywhere. My source is personal communication from one of the NONRomark researchers involved in the study and he did not give me data on which that currently speculative mechanism was based.
Cancer risk of riba - see above.
Hallo, it indeed seems to have a favorable tox profile and I would not hesitate to take nitazoxanide myself, if it was available here. This statement should give a feeling about my estimation. No CYP450 and so on, great. No P-glycoprotein drug interactions too, right?
I do not want to construct any wild speculations about sides or interactions, it lookes harmless.
My hesitation for any off-label combo under the management of patients themselves may be a little bit too anxious. If someone has only a hammer, the one always thinks the problem is a nail ;-) I am working in the field of marketing authorisation since 15 years, could be that I lost a pragmatic view for things like this.
Nevertheless I collect some off-label documentation in another indication here too. Physicians document the effect of individual methylphenidate therapy for some people with therapy refractory post-hepatitis fatigue. Some patiente have a much better quality of live since they take it. If these pioneer results are promissing, clinical studies phase III will follow. It is helpful if there is a very good documentation by a physician.
However, even if things seem to be very clear and simple, there may be bad surprises. To my knowledge the phase I researchers of TGN1412 in London did not make a single mistake, toxicity had been tested forward and backwards before, they just couldn
If you were treating and decided to add Alina to your mix with combo therapy, how long would you take it? I noticed you said you would do it short term.